In the eighth installment of the OFID podcast, Editor Paul Sax, MD, delves into the headline-making pyrimethamine (Daraprim) saga where Turing Pharmaceuticals increased the price of the recently-acquired toxoplasmosis drug from $13 to $750 a pill. Aaron Kesselheim, MD, JD, MPH, and Joel Gallant, MD, MPH, join the discussion to shed light on what is unique about the generic drug market in the U.S. that makes these dramatic price increases possible and if there will be any resolution.